CoLucid Rakes in $25M for Migraine Treatment

Image via Wikipedia

CoLucid announced it closed a $25M series B financing. The main phase 2, development compound is COL-144 (5-HT1F agonist for the treatment of migraine), a drug they in-licensed from Eli Lilly after it completed phase 1 trials.
While the $25M series B headline immediately caught my eye, it didn’t take much more reading [...]

Treximet… Finally!

I’ve been having migraines lately, well for the last few years. Terrible migraines. Migraines so debilitating only a combination of acutely acting medicines could even touch the pain. The problem was, up until now (finally, after a two year delay), I had to open two bottles of medicine, remove a few pills [...]